Italfarmaco and VeriSIM Life will combine AI and HDAC expertise in a preclinical drug discovery deal worth over USD 100 ...
Vaxcyte says its 31-valent VAX-31 vaccine met all primary endpoints in the OPUS-1 Phase III trial in adults aged 50 and older. Read the topline results.
Alector will receive $100M upfront as Genentech gains worldwide rights to its brain-penetrant GCase therapy for Parkinson’s.
Italfarmaco has licensed JCR’s brain-penetrating Hunter syndrome therapy for the US, Europe and Latin America. Read the details of the international deal.
U.S. cancer death rates fell through 2023, led by lung cancer gains, according to a new national report. Read the key ...
The FDA approved Jaypirca for first-line CLL/SLL, following trial results showing an 80% reduction in progression risk. See ...
Researchers found that FAH’s nuclear function can drive CDK4/6 inhibitor resistance in HR+ breast cancer. Read what the ...
Celaid Therapeutics raised JPY 400m from Shionogi and Teikoku Ventures to prepare CLD-001 for US clinical trials. Read the ...
Sernova and Seraxis closed $11.2 million to fund merger and advance BetaNova’s type 1 diabetes cell therapy into Phase 1/2 ...
Shionogi will acquire IntraBio for $2 billion upfront, adding AQNEURSA for rare neurological diseases. See what the deal means for its portfolio. Read more.
Learn how AnnJi is advancing AJ201 into the Phase III ROMA-KD trial for SBMA in the US, a disease with no approved treatment. Read the latest update.
Nhwa licensed its sleep-disorder drug to Somnivera outside Greater China in a deal worth up to $517 million. Read key deal terms and milestone details.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results